Biogen R&D increased by 5.8% to $539.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.2%, from $434.10M to $539.00M. Over 4 years (FY 2021 to FY 2025), R&D shows a downward trend with a -8.2% CAGR.
Analysis
How to read this metric
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Detailed definition
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Peer comparison
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
research_and_developmentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $585.10M | $702.40M | $699.50M | $551.70M | $528.60M | $549.20M | $601.60M | $570.60M | $584.20M | $736.30M | $570.90M | $452.90M | $513.90M | $542.70M | $532.30M | $434.10M | $399.00M | $436.10M | $509.40M | $539.00M |
| QoQ Change | — | +20.0% | -0.4% | -21.1% | -4.2% | +3.9% | +9.5% | -5.2% | +2.4% | +26.0% | -22.5% | -20.7% | +13.5% | +5.6% | -1.9% | -18.4% | -8.1% | +9.3% | +16.8% | +5.8% |
| YoY Change | — | — | — | — | -9.7% | -21.8% | -14.0% | +3.4% | +10.5% | +34.1% | -5.1% | -20.6% | -12.0% | -26.3% | -6.8% | -4.2% | -22.4% | -19.6% | -4.3% | +24.2% |
Product Breakdown
| Segment | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|---|
| QALSODY | — | — | — | $4.00M | $5.00M | $5.00M | $5.00M | $5.00M |
| ADUHELM | $83.75M | $83.75M | $83.75M | — | — | — | — | — |
| Mosunetuzumab | $7.10M | $7.10M | $7.10M | — | — | — | — | — |
| QALSODY EU | — | — | — | — | $5.00M | $5.00M | $5.00M | — |
| QALSODY Japan | — | — | — | — | $2.50M | $2.50M | $2.50M | — |
| SOD1 | $4.25M | $4.25M | $4.25M | — | — | — | — | — |
| Total | $551.70M | $528.60M | $549.20M | $570.90M | $452.90M | $513.90M | $542.70M | $532.30M |
Mosunetuzumab, QALSODY, QALSODY EU, QALSODY Japan, SOD1 are derived from annual filings.
QALSODY was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $176.40M | $221.50M | $186.90M | $178.50M | $168.20M | $167.10M | $179.10M | $172.80M |
| Total | $513.90M | $542.70M | $532.30M | $434.10M | $399.00M | $436.10M | $509.40M | $539.00M |
R&D at Other Companies
Frequently Asked Questions
- What is Biogen's r&d?
- Biogen (BIIB) reported r&d of $539.00M in Q1 2026.
- How has Biogen's r&d changed year-over-year?
- Biogen's r&d increased by 24.2% year-over-year, from $434.10M to $539.00M.
- What is the long-term trend for Biogen's r&d?
- Over 4 years (2021 to 2025), Biogen's r&d has grown at a -8.2% compound annual growth rate (CAGR), from $2.50B to $1.78B.
- What does r&d mean?
- The money spent on creating new technology and improving existing products.